Inflammatory Disease News and Research

RSS

Researchers to develop new diagnostics platform for early detection of lung cancer

The earlier cancers can be detected, the better the chances of a cure. Researchers are now working to develop a new diagnostics platform with which the illness can be diagnosed in its early stages, even during a visit to the general practitioner: protein biomarkers in exhaled air divulge the presence of pathological cells in the lung.

3 Feb 2011

Pervasis to present PVS-10200 interim data from Phase 1/2 PAD clinical study at IC3D

Pervasis Therapeutics, Inc. today announced it will present interim data from the company's Phase 1/2 clinical study of PVS-10200, an investigational cell-based therapy under development to prevent restenosis in patients with peripheral arterial disease (PAD) who undergo an angioplasty and stent procedure in the superficial femoral artery.

21 Jan 2011

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis.

20 Jan 2011

Healthy teeth and gums may reduce risk for pneumonia, chronic obstructive pulmonary disease

Maintaining periodontal health may contribute to a healthy respiratory system, according to research published in the Journal of Periodontology. A new study suggests that periodontal disease may increase the risk for respiratory infections, such as chronic obstructive pulmonary disease (COPD) and pneumonia.

19 Jan 2011

Inflammation “master switch” found: Study

According to the latest medical discovery a protein that acts as a “master switch” has been found to determine whether certain white blood cells will boost or dampen inflammation. This may open new avenues in rheumatoid arthritis research. Rheumatoid arthritis or RA is an inflammatory disease that causes severe progressive crippling of the joints.

17 Jan 2011

Enlight Biosciences forms new oral drug delivery technology company

Entrega, Inc., a new company developing oral drug delivery technologies, today announced its formation by Enlight Biosciences, a Boston-based company established in partnership with a group of leading global pharmaceutical companies.

10 Jan 2011

BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer

BIND Biosciences announced today that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of BIND-014 in cancer patients. BIND-014, the first product candidate to enter clinical evaluation from BIND's broad proprietary Medicinal Nanoengineering platform, is a targeted polymeric nanoparticle containing the cytotoxic agent, docetaxel.

7 Jan 2011

Findings of AM095 in various in vitro, in vivo models of fibrotic disease published in JPET

Amira Pharmaceuticals, Inc. announced today the publication of its findings in the Journal of Pharmacology and Experimental Therapeutics which describes the biologic effects and the characterization of AM095, a lysophosphatidic acid receptor 1 antagonist, in various in vitro and in vivo models of fibrotic disease.

6 Jan 2011

Study compares treatment cost of PID hospitalizations, ER care for teen girls

Hospitalizing teen girls with pelvic inflammatory disease costs six times as much as treating them in the emergency room, and up to 12 times more than treating them in an outpatient clinic, according to a small study conducted at the Johns Hopkins Children's Center.

6 Jan 2011

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Genentech, Inc., a member of the Roche Group, today announced that the United States Food and Drug Administration has extended the ACTEMRA (tocilizumab, RoACTEMRA in the European Union) label to include inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in adult patients with moderately to severely active rheumatoid arthritis, when given in combination with methotrexate.

6 Jan 2011

P. gingivalis infection accelerates inflammation and atherosclerosis in the innominate artery

Atherosclerosis is the leading cause of death in the developed world. While a number of risk factors for atherosclerosis have been defined, scientists continue to study other possible risk factors for this disease. Recent epidemiological and experimental studies link infectious agents with the development of inflammatory atherosclerosis. A hallmark of chronic infection with the oral pathogen Porphyromonas gingivalis is the induction of a chronic inflammatory response.

5 Jan 2011

Researchers discover recycling mechanism of signaling receptors

An international team of researchers led by Carnegie Mellon University's Manojkumar Puthenveedu has discovered the mechanism by which signaling receptors recycle, a critical piece in understanding signaling receptor function. Writing in the journal Cell, the team for the first time describes how a signaling receptor travels back to the cell membrane after it has been activated and internalized.

23 Dec 2010

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.

23 Dec 2010

Altering balance among immune system cells could hold potential for T2D-associated inflammation treatment

Researchers from Boston University School of Medicine (BUSM) have demonstrated that certain T cells require input from monocytes in order to maintain their pro-inflammatory response in people with type 2 diabetes (T2D). The study also showed, for the first time, how a loss in homeostasis in this group of T cells most likely promotes chronic inflammation associated with T2D.

22 Dec 2010

Amira identifies novel pre-clinical candidate for autotaxin lysophosphatidic acid related program

Amira Pharmaceuticals, Inc. announced today that it has successfully identified a novel pre-clinical candidate for its newest lysophosphatidic acid (LPA)-related program, autotaxin. Autotaxin is an enzyme upstream from LPA receptors and has been implicated in a number of diseases including rheumatoid arthritis, glioblastoma, lung, breast, ovarian and thyroid cancers.

17 Dec 2010

BELLUS Health, Celtic Therapeutics initiate KIACTA global confirmatory phase III clinical study for AA amyloidosis

BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.

16 Dec 2010

BRIC researchers discover new protein that improves immune system

Researchers at BRIC, the University of Copenhagen, have discovered for the first time a protein normally found in the body that can act to prevent chronic tissue inflammation.

15 Dec 2010

Amira's clinical-stage DP2 receptor antagonist program data to be presented at Pacifichem 2010

Amira Pharmaceuticals, Inc. announced today that it will present preclinical and clinical data from its DP2 receptor antagonist program on December 17, 2010, at Pacifichem 2010 in Honolulu, Hawaii. The data from Amira's clinical-stage DP2 program will be delivered by Brian Stearns, Ph.D., in a presentation titled "Discovery and optimization of a novel series of DP2 antagonists with efficacy in mouse models of COPD and asthma."

15 Dec 2010

Mouse study shows flu virus infection may protect against asthma

In a paper that suggests a new strategy to prevent asthma, scientists at Children's Hospital Boston and their colleagues report that the influenza virus infection in young mice protected the mice as adults against the development of allergic asthma.

14 Dec 2010

Phase 2 study data of ALD518 demonstrates reversal of anemia in NSCLC patients

Alder Biopharmaceuticals Inc. today announced that data from a Phase 2 study of its ALD518 investigational antibody therapeutic that targets interleukin-6 (IL-6) demonstrate a reversal of anemia in patients with advanced non-small cell lung cancer.

9 Dec 2010

Inflammatory Disease News and Research

Researchers to develop new diagnostics platform for early detection of lung cancer

Pervasis to present PVS-10200 interim data from Phase 1/2 PAD clinical study at IC3D

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

Healthy teeth and gums may reduce risk for pneumonia, chronic obstructive pulmonary disease

Inflammation “master switch” found: Study

Enlight Biosciences forms new oral drug delivery technology company

BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer

Findings of AM095 in various in vitro, in vivo models of fibrotic disease published in JPET

Study compares treatment cost of PID hospitalizations, ER care for teen girls

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

P. gingivalis infection accelerates inflammation and atherosclerosis in the innominate artery

Researchers discover recycling mechanism of signaling receptors

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Altering balance among immune system cells could hold potential for T2D-associated inflammation treatment

Amira identifies novel pre-clinical candidate for autotaxin lysophosphatidic acid related program

BELLUS Health, Celtic Therapeutics initiate KIACTA global confirmatory phase III clinical study for AA amyloidosis

BRIC researchers discover new protein that improves immune system

Amira's clinical-stage DP2 receptor antagonist program data to be presented at Pacifichem 2010

Mouse study shows flu virus infection may protect against asthma

Phase 2 study data of ALD518 demonstrates reversal of anemia in NSCLC patients

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News